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Non-invasive 19F NMR analysis of a protein-templated N-
acylhydrazone dynamic combinatorial library 
Alexander G. Ekström, Jue Theresa Wang, Juraj Bella and Dominic J. Campopiano 
Dynamic combinatorial chemistry (DCC) is a powerful tool to identify ligands for biological targets. We used 
19F NMR as an in situ, non-invasive technique for measuring the composition of a dynamic combinatorial 
library (DCL) of N-acylhydrazones (NAHs). An NAH DCL, constructed from a fluoro-aromatic aldehyde and a 
small set of hydrazides, was targetted at ecFabH, an essential enzyme in bacterial fatty acid biosynthesis. 
Our NMR analysis identified a tert-butyl NAH as the best binder which was confirmed by enzymatic assay. 
Introduction 
Dynamic combinatorial chemistry (DCC) is a technique derived 
from fragment-based screening that exploits chemically-
reversible reactions to generate a thermodynamically 
equilibrated library from a pool of building blocks1. The 
reversibility of the dynamic combinatorial library (DCL) allows 
perturbation of the equilibrium through the addition of a 
template. Since its inception, DCC has been applied to a variety 
of fields including self-assembly systems, dynamic polymers and 
host-guest chemistry, however an exciting application is in the 
field of drug discovery, whereby a protein is used to self-select 
a ligand through amplification of the best binding species at the 
expense of other combinations (see fig. 1). 
 The constantly expanding toolbox of DCC-compatible 
reversible reactions2,3 has helped facilitate the wide range of 
applications of the technique as a whole, however the number 
of bio-compatible reactions is limited by the requirement for 
the reaction to proceed on a reasonable timescale under 
physiological conditions (temperature, solvent, pH). From this 
panel of suitable reactions, the chemistry of N-acylhydrazone 
(NAH) exchange has been well documented and successfully 
used to identify ligands for a number of different protein 
targets4–8. The reaction between an aldehyde and a hydrazide 
occurs rapidly at pH 4 with an equilibrium constant and stability 
that strongly favours product formation9. In order to allow the 
reaction to proceed at a physiologically relevant pH, Bhat et al. 
applied early work from Jencks on oxime exchange catalysis10. 
By using aniline as a nucleophilic catalyst they showed that their 
10-member N-acylhydrazone library equilibrated within a few 
hours at pH 6.25,10,11. 
 
 
Figure 1. Formation of a DCL and analysis of the blank and 
protein-templated DCL product distribution by 19F NMR. 
 
 A DCC experiment typically involves 3 main steps: firstly, the 
DCL is equilibrated under conditions promoting a 
thermodynamic equilibrium. Secondly, the protein template is 
added and the DCL is allowed to re-equilibrate establish a new 
product distribution. Thirdly, the final and arguably most vital 
step, is the analysis of the DCL in the presence and absence of 
the template. Various techniques to deconvolute the library 
mixture have been demonstrated12, including HPLC5,13–15, mass 
spectrometry8,16–18 and 1H NMR and Saturation Transfer 
Difference (STD) NMR7,19,20, dynamic deconvolution21 and X-ray 
crystallography22. Recent reviews of this area have highlighted 
both experimental and theoretical approaches used to analyse 
DCLs12,23. 
 The main difficulty lies in not perturbing the DCL during the 
analysis. This has previously been achieved by either chemically 
or kinetically freezing the exchange reaction. For example, NAH 
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exchange is effectively stopped by increasing the pH to 9. The 
second hurdle is ensuring that the complete product population 
is analysed. This problem is exemplified in HPLC analysis of 
protein-templated DCL, where the protein must be removed 
from the mixture prior to analysis to prevent column fouling5. 
In the absence of denaturation agents which may perturb the 
finely balanced protein-templated DCL equilibrium, target 
binders may remain bound to the protein and are excluded 
from the DCL analysis. This technique of “ligand fishing” has in 
fact been demonstrated in the DCC context to find competitive 
inhibitors of lysozyme24. 
 Analysis by non-denaturing electrospray ionisation mass 
spectrometry (ESI-MS) has been demonstrated in a number of 
elegant DCC experiments8,20,25, however the technique relies on 
the protein ionising efficiently under non-denaturing conditions 
and is therefore not universal. STD-NMR has also been used to 
identify binders from a DCL, however the technique requires 
upwards of a 20-fold molar excess of ligand. At such 
stoichiometry, STD experiments do not leverage the dynamic 
self-selection qualities central to the DCC concept. Instead, they 
exploit NAH formation as a facile, one-pot synthetic route to a 
library of compounds for binding assay. With the exception of 
STD-NMR, the aforementioned techniques are all destructive in 
a sense that a portion of the DCL is consumed in the analysis.  
 Our preliminary HPLC analyses of a protein-templated NAH 
DCL delivered striking differences in the product distribution 
depending on the method of protein removal (see fig. S1). To 
resolve this discrepancy, we set out to employ a non-destructive 
technique that would allow the DCL composition to be 
monitored in pseudo real-time. 
 Fluorine has become a central part of drug discovery, with 
approximately 25% of all marketed drugs containing at least one 
fluorine atom26. As a bioisostere of hydrogen, its inclusion can 
help medicinal chemists to modulate the pharmacokinetic, 
pharmacodynamic and physical binding properties of a 
compound26. Subsequently 19F NMR has developed into a 
popular technique for screening fluorine-based fragment 
libraries, with the ability to screen up to 20 fragments in one 
experiment. The high gyromagnetic ratio and chemical shift 
anisotropy of the 19F nucleus allow for well-resolved signals that 
relay information on protein binding through signal broadening 
or chemical shift perturbation. The scarce biological abundance 
of 19F allows for background-free spectra, unaffected by 
protonated buffers and solvents, to be recorded in minutes on 
a low-field NMR spectrometer. The caveat of 19F screening is the 
requirement of individual well-resolved signals. This can be 
achieved though intelligent library design facilitated by 
increasingly accurate chemical shift prediction software (e.g. 
MNova, TopSpin). More complex NMR experiments have been 
used to resolve overlapping signals, both by 2D homonuclear 
correlation-ordered experiments (1H-19F COSY) and pseudo-2D 
diffusion-ordered (19F DOSY) experiments, where the signals are 
separated on second axis by diffusion coefficient26–28. The 
elegance of 19F NMR analysis has already been demonstrated in 
a number of abiotic DCC examples29–31. This method was also 
used to monitor binding of a 4-component imine library to a 
domain of a human -catenin target32. Herein, we describe our 
design and analysis of a protein-templated NAH DCL to further 
demonstrate the additional advantages of 19F NMR in DCC for 
drug discovery. 
Results and Discussion 
We chose to design a library targeting -ketoacyl-ACP synthase 
III (FabH) from E. coli, the initial condensing enzyme in bacterial 
fatty acid biosynthesis (FAS II). Although the active site residues 
and primary sequence remain highly conserved across both 
Gram-positive and Gram-negative bacteria, small differences in 
the binding pocket architecture determine the substrate 
specificity across bacterial species. This makes FabH a plausible 
target for novel narrow-spectrum antibiotics33. There are 
currently few known FabH inhibitors, and none that report good 
in vivo efficacy34–36. Zhang et al. have recently published a 
number of reports on the discovery of NAH inhibitors targeting 
FabH where each compound was prepared individually by 
organic synthesis. Since each molecule was composed of A-B 
ring systems joined by an NAH linker it provided the basis 
around which our dynamic library was designed37–41. 
 
Figure 2. Rationale for the DCL and composition of the 5-
membered proof-of-concept 19F-labelled DCL. Hydrazide 1 
(isoniazid) is a front-line TB therapy with another FAS II target. 
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Figure 3. Validation of 4-APA as an alternative to aniline. Fig. 3a shows the formation of NAH A4 from aldehyde A and hydrazide 4 
over time in the presence of different concentrations of aniline. Figure 3b shows the same experiment, catalysed by different 
concentrations of 4-APA. The data shown is a compilation of the NAH A4 HPLC peaks recorded at given time points (see fig. S3).
Figure 4. 19F NMR spectra of the 19F-labelled DCL: a) the DCL equilibrated in the absence of the protein target, b) the protein-
templated DCL equilibrated in the presence of FabH. 
 The 5-membered proof-of-concept library was based 
around commercially available fluoro-aromatic aldehyde A as 
the central core along with five commercially available aromatic 
hydrazides 1-5 with differing chemical and physical properties 
(Fig.2). The high degree of conjugation through the system 
allowed us to observe sufficiently resolved 19F chemical shifts of 
individual NAHs despite the differences in chemistry being up to 
13 bonds away42 (see Fig. S2). 
 To minimise the time required to reach equilibrium, the use 
of aniline as a nucleophilic catalyst for NAH exchange was 
introduced by Dawson11, and has since been successfully used 
in many protein-templated DCC experiments5,6. From 
preliminary 1H-STD-NMR experiments we observed that aniline 
was binding to FabH and would potentially interfere with the 
DCL. Issues with aniline were noted by Blanden et al. in their 
attempts to optimise hydrazone ligation for biomolecular 
labelling. They identified 4-amino-L-phenylalanine (4-APA) as a 
suitable replacement for aniline so we investigated if 4-APA 
could be substituted for aniline in a DCL43. We validated that 4-
APA has comparable catalytic efficiency to aniline with our NAH 
DCL, both in the forward reaction (Fig. 3 and S4) and the reverse 
reaction (Fig. S5). When a library is prepared from product A5 
and hydrazides 3 and 4 (see Fig. 2), the same product 
distribution is observed as when a library is prepared from 
hydrazides 3, 4 and 5 and aldehyde A (Fig. S4 and S5). Binding 
of 4-APA to FabH was not observed by 1H-STD-NMR. 
 The DCL was assembled with each of the hydrazides 1-5 and 
aldehyde A at a final concentration of 200 μM, buffered at pH 
6.2 using 50 mM sodium phosphate buffer with 10% DMSO and 
3 mM 4-APA. The DCL cocktail was spiked with 200 μM 5-
fluorouracil as an internal reference and either 200 μM ecFabH 
or an equivalent volume of buffer. Each library was transferred 
to an NMR tube and a 19F spectrum was acquired every two 
hours over a twelve-hour period. In agreement with the 4-APA 
characterisation experiment (Fig. 3), the DCL reached 
equilibrium within 2 hours. Fig. 4a shows the blank library 8 
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hours after mixing. Notably not all products are at an equal 
concentration, suggesting the electronic substituents of the ring 
have an effect on the intrinsic thermodynamic stability of each 
NAH. Fig. 4b shows the 19F spectrum of the library templated by 
the target, ecFabH. Slight signal broadening is observable for all 
DCL members, suggesting a slow exchange process is occurring 
between bound and unbound ligand states. Most impressively, 
the signal broadening and upfield chemical shift perturbation of 
compound A4 is indicative of the compound being present in its 
bound state at a relatively higher proportion to the other library 
members27. 
 It must be noted that there are two opposing forces at play 
when considering signal integral: on one hand Le Chatelier’s 
principle will strive toward a product distribution proportional 
to the depth of the energy well of each species, although this is 
not always the case2. Therefore, if product A4 is selected by the 
protein its relative concentration and corresponding signal 
integral should increase. Concomitantly, the signal broadening 
resulting from exchange between chemical shifts corresponding 
to bound and unbound states of the ligand may present itself as 
an apparent integral decrease of the bound ligand. Due to the 
breadth and low intensity of the bound state signal we have as 
yet been unable to determine the chemical shift of the bound 
state by 19F COSY-NMR. This method is therefore not strictly 
quantitative, but acts as a qualitative indicator of potential 
binders whose properties can be further characterised by 
quantitative techniques.  
 Using individually synthesised DCL members an in vitro 
assay validated the results from the 19F NMR DCC experiment. 
All 5 NAHs showed inhibitory activity at concentrations of 3 
mM. Gratifyingly, compound A4 showed the strongest 
inhibition, causing a 50% decrease in activity at 3 mM compared 
to the DMSO vehicle control and the FabH inhibitor HR45 as a 
negative control44,45 (Fig. S6). That such a weak inhibitor could 
have been picked out of the NMR analysis is encouraging. It also 
leads to the question of what effect would a tight nM binder 
have? Broadening of the signal such that it disappears 
altogether into the baseline may also be useful in identifying 
hits by comparison with protein-free controls. We do not seek 
to claim that the NAH molecules described here may be of 
therapeutic value, rather we present this as a proof of concept 
that 19F NMR analysis can be used to interrogate an NAH DCL 
derived from a an appropriately F-labelled building block. 
Conclusions 
In summary, we have demonstrated a non-invasive analysis of a 
protein-templated DCL by 19F NMR, using 4-APA as a biologically 
benign alternative to aniline-catalysed NAH exchange. The 
results from the DCL agreed well with preliminary inhibition 
data from an in vitro FabH assay. Screening of much larger 
compound libraries will no doubt require multiple methods to 
identify, then validate, hit molecules. A combination of 19F 
fragment screening and MS-based methods are complementary 
analytical tools suitable for protein-templated DCC. 
Development of such rapid, cost-effective, and universal 
methods should help DCC become more widely used in hit 
discovery. 
Experimental 
Nuclear magnetic resonance (NMR) spectra were recorded at 
298 K on Bruker PRO500, AVA400 or AVA500 spectrometers 
running at 500 MHz (1H spectra), 126 MHz (12C spectra) or 94 
MHz (19F spectra). Chemical shift values () are reported in parts 
per million (ppm) relative to tetramethylsilane (TMS = 0 ppm) 
and are referenced to the residual solvent peak, or to the signal 
of internal standard 5-fluorouracil (5FU = -169.19 ppm) in the 
case of the 19F-labelled DCL. 1H NMR data are reported in the 
format: chemical shift, relative intensity, multiplicity (s = singlet, 
d = doublet, t = triplet, m = multiplet, br = broad), coupling 
constant (J value, Hz), and assignment. 13C NMR data are 
reported in the format: chemical shift and assignment. 
 
Expression and purification of ecFabH. The ecFabH/pET-28a 
construct (4 μL) was transformed into an aliquot (50 μL) of 
BL21(DE3) cells and set on ice for 25 minutes. The cells were 
heat shocked at 42 °C for 40 seconds and set back on ice for a 
further 2 minutes. SOC media (100 μL) was added and the 
mixture was agitated at 37 °C for 1 hour. The mixture was 
spread on LB agar (30 μg/mL kanamycin) and incubated 
overnight at 37 °C. A single transformant was used to inoculate 
two seed cultures of sterile LB broth (2 x 250 mL, 30 μg/mL 
kanamycin) and agitated overnight at 37 °C. One of the 
overnight seed cultures was used to sub-culture sterile LB broth 
(5 x 500 mL, 30 μg/mL kanamycin) to an OD600 of 0.1. The 
cultures were agitated at 37 °C until the OD600 reached 0.6, at 
which point expression was induced by addition of IPTG (final 
conc. 0.1 mM). Cells were harvested after a further 3 hours at 
30 °C and subsequently stored at -20 °C. 
N-terminal histidine-tagged ecFabH was purified at 4 °C by 
Ni-affinity chromatography followed by size exclusion 
chromatography. The BL21 (DE3) cell pellet expressing ecFabH 
was resuspended in lysis buffer (30 mL, 20 mM Tris-HCl pH 7.6, 
300 mM NaCl, 5 mM imidazole) and lysed for 15 minutes with 
rounds of 30 second of sonication followed by 30 seconds of 
rest. The cell lysate was clarified by centrifugation (18,000 g, 30 
minutes, 4 °C) and the cell-free extract was injected onto a 
HisTrap 5 mL (GE Healthcare) Ni2+-affinity chromatography 
column pre-equilibrated in lysis buffer. The column was washed 
with lysis buffer (5 CV) before the histidine-tagged protein was 
eluted using a gradient (0-100%) of lysis buffer to elution buffer 
(20 mM Tris-HCl pH 7.6, 300 mM NaCl, 400 mM imidazole) over 
20 CV. Each elution fraction was analysed by SDS-PAGE, and the 
fractions containing His-tagged ecFabH were pooled, and 
concentrated to a volume less than 5 mL. ecFabH was further 
purified by size exclusion chromatography (HiLoad Superdex 
200 16/60, GE Healthcare) with an isocratic elution of mobile 
phase buffer (20 mM Tris-HCl pH 7.6, 100 mM NaCl, 10% 
glycerol) at 1 mL/min over 120 minutes. ecFabH eluted at 
approximately 70 minutes and the most concentrated fractions 
were pooled and flash frozen and stored at -80 °C. 
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DCL conditions. The library was assembled with each of the 
hydrazides 1-5 and aldehyde A at a final concentration of 200 
μM, buffered at pH 6.2 using 50 mM sodium phosphate with 
50% D2O, 10% DMSO, 50 mM NaCl and 3 mM 4-APA. The library 
cocktail also contained 200 μM 5-fluorouracil as a non-
competing internal reference and either 200 μM ecFabH or an 
equivalent volume of enzyme purification buffer. Each library 
was transferred to an NMR tube and a 19F spectrum (94 MHz, 
512 scans, T1 = 1 second) was acquired every two hours over a 
twelve-hour period.  
 
Length of relaxation time in 19F NMR pulse sequence. A three-
member library was assembled from N-acylhydrazones A1, A3 
and A5 (200 μM each) in sodium phosphate buffer (50 mM, D2O, 
pH 6.2), 5-fluorouracil (internal standard, 200 μM) and a total of 
10% DMSO. A series of 19F NMR experiments were conducted 
with 512 scans and relaxation times of 1, 2, 3 or 4 seconds. The 
integral of the signals corresponding each N-acylhydrazone 
relative to the internal standard were compared at different 
relaxation times to determine the required relaxation time for 
the DCL 19F NMR experiment. No difference in relative signal 
integral was apparent between all T1 intervals, therefore a T1 of 
1 second was used in the DCL experiments. 
 
FabH assay. The activity of FabH was quantified by 5,5-dithio-
bis-(2-nitrobenzoic acid) (DTNB) assay with the following 
procedure. An assay cocktail was prepared from DTNB (1 mL, 4 
mM in 50 mM NH4OAc), HEPES buffer (1 mL, 1 M, pH 8.0) and 
ddH2O (8 mL). The assay was run in 96-well plate format with 
the following protocol (the following bracketed figures refer to 
final concentrations): 100 μL DTNB assay cocktail, 25 μL ecFabH 
(0.63 μM), 25 μL Acetyl-CoA (375 μM), 25 μL Malonyl-CoA (375 
μM), 5 μL ddH2O, 20 μL NAH A1-A5 (3 mM) or HR45 (200 μM) in 
DMSO or DMSO control. Following 20 mins incubation at 37 °C, 
the reaction was initiated by the addition of malonyl-CoA and 
followed by monitoring absorbance change at 412 nm over 20 
mins at 37 °C. The DMSO concentration was maintained at 10% 
to aid the solubility of the NAH compounds. 
 
General procedure for the synthesis of N-acylhydrazones A1-
A5. 2-Fluoro-5-formylbenzoic acid (50 mg, 0.30 mmol, 1.0 eq.) 
and the hydrazide (0.33 mmol, 1.1 eq.) were dissolved in 
ethanol (2 mL). A few drops of glacial acetic acid were added 
and the mixture was stirred overnight at room temperature. 
The solid formed was collected by vacuum filtration and washed 
in diethyl ether (5 mL) and water (5 mL) to yield the target N-
acylhydrazone as a white solid. 
A1 (54 mg, 0.188 mmol, 63%): m.p. 263-264°C; IR (nujol, cm-1) 
3497, 3402, 3196, 3073, 3028, 1657, 1612, 1564; 1H NMR (500 
MHz, DMSO) δ 12.17 (1H, s, OH-1), 8.83–8.78 (2H, m, CH-15,17), 
8.50 (1H, s, CH-9), 8.27 (1H, m, CH-5), 8.02–7.99 (1H, m, CH-8), 
7.86–7.81 (2H, m, CH-14,18), 7.44 (1H, dd, J = 10.6, 8.6 Hz,  
CH-6); 13C NMR (126 MHz, DMSO) δ 165.1, 162.3, 150.8, 147.5, 
140.8, 133.8, 131.1, 130.9, 112.0, 118.4, 118.2; 19F NMR (470 
MHz, DMSO) δ -110.58; HRMS m/z (ESI+) calcd. C14H10FN3O3 
[M+Na]+ requires 310.0598, found 310.0599. 
A2 (72 mg, 0.251 mmol, 84%): m.p. 265-266°C; IR (nujol, cm-1)  
3196, 3065, 2446, 2426, 1647, 1618, 1601, 1553; 1H NMR (500 
MHz, DMSO) δ 12.12 (1H, s, OH-1), 9.10–9.05 (1H, m, CH-18), 
8.78 (1H, d, J = 3.7 Hz, CH-16), 8.48 (1H, s, CH-9), 8.28–8.26 (2H, 
m, CH-5,14), 7.59 (1H, dd, J = 7.8, 4.9 Hz, CH-15), 7.44 (1H, dd,  
J = 10.5, 8.6 Hz, CH-6); 13C NMR (126 MHz, DMSO) δ 165.6, 
165.1, 152.9, 149.1, 146.9, 136.0, 133.7, 131.2, 130.8, 129.6, 
124.1, 120.5, 118.4, 118.4, 118.2, 31.2; 19F NMR (470 MHz, 
DMSO) δ -110.75; HRMS m/z (ESI+) calcd. C14H10FN3O3 [M]+ 
requires 288.0779, found 288.0786. 
A3 (82 mg, 0.259 mmol, 87%): m.p. 223-224°C; IR (nujol, cm-1) 
3401, 3225, 2995, 1701, 1659, 1618, 1589, 1545; 1H NMR (500 
MHz, DMSO) δ 11.91 (1H, s, OH-1), 8.49 (1H, s, CH-9), 8.27–8.21 
(1H, m, CH-5), 7.98 (1H, s, CH-8), 7.51–7.38 (4H, m, CH-
14,15,16,18), 7.21–7.15 (1H, m, 6), 3.85 (3H, s, CH3-19); 13C NMR 
(126 MHz, DMSO) δ 165.1, 163.47, 161.3, 159.7, 146.3, 135.2, 
133.6, 131.4, 130.7, 130.2, 120.5, 120.3, 118.3, 118.1, 118.1, 
113.4, 55.9, 31.2; 19F NMR (470 MHz, DMSO) δ -110.97; HRMS 
m/z (ESI+) calcd. C16H13FN2O4 [M+Na]+ requires 339.0752, found 
339.0755. 
A4 (33 mg, 0.096 mmol, 32%): m.p. 230-232°C; IR (nujol, cm-1) 
3441, 3289, 2953, 2619, 2596, 1701, 1612, 1557, 1503; 1H NMR 
(500 MHz, DMSO) δ 11.88 (1H, s, OH-1), 8.48 (1H, s, CH-9), 8.24 
(1H, d, J = 6.9 Hz, CH-5), 7.99–7.96 (1H, m, CH-8), 7.86 (2H, d, J 
= 8.1 Hz, CH-14,18), 7.56 (2H, d, J = 8.3 Hz, CH-15,17), 7.42 (1H, 
m, CH-6), 1.33 (9H, s, CH3-19,20,21); 13C NMR (126 MHz, DMSO) 
δ 172.4, 165.1, 164.0, 146.0, 144.2, 130.6, 128.0, 125.8, 120.4, 
118.1, 35.2, 31.4, 31.2, 21.5; 19F NMR (470 MHz, DMSO) δ -
111.08; HRMS m/z (ESI+) calcd. C19H19FN2O3 [M]+ requires 
343.1453, found 343.1455. 
A5 (72 mg, 0.226 mmol, 73%): m.p. 260-263°C; IR (nujol, cm-1) 
3292, 3092, 1695, 1651, 1618, 1589, 1557, 1520; 1H NMR (500 
MHz, DMSO) δ 11.71 (1H, s, OH-1), 9.71 (1H, s, OH-20), 8.47 (1H, 
s, CH-5), 8.23 (1H, dd, J = 7.3, 2.3 Hz, CH-8), 7.95 (1H, d, J = 6.7 
Hz, CH-6), 7.48–7.44 (1H, m, CH-18), 7.44–7.38 (1H, m, CH-14), 
6.89 (1H, d, J = 8.2 Hz, CH-15), 3.86 (3H, s, CH3-19); 13C NMR (126 
MHz, DMSO) δ 165.1, 163.2, 161.1, 150.7, 147.8, 133.4, 133.3, 
131.6, 130.5, 124.5, 121.9, 120.4, 120.3, 118.3, 118.1, 115.5, 
112.2, 56.3, 19.0; 19F NMR (470 MHz, DMSO) δ -111.21; HRMS 
m/z (ESI+) calcd. C16H13FN2O5 [M+Na]+ requires 355.0701, found 
355.0705. 
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